Ribociclib Plus Switch Endocrine Therapy Elicits Benefit After CDK4/6 Progression in HR+/HER2– Metastatic Breast Cancer
June 5th 2022
Ribociclib plus endorcrine therapy led to a statistically significant improvement in progression-free survival in patients with hormone receptor–positive, HER2-negative unresectable or metastatic breast cancer with tumor progression following treatment with a CDK4/6 inhibitor, according to findings from the randomized phase 2 MAINTAIN trial.